Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

被引：0
|
作者：
Weisel, K. [1 ]
Palumbo, A. [2 ]
Chanan-Khan, A. [3 ]
Nooka, A. K. [4 ]
Spicka, I. [5 ]
Masszi, T. [6 ]
Beksac, M. [7 ]
Hungria, V. [8 ]
Munder, M. [9 ]
Mateos, M-V. [10 ]
Mark, T. M. [11 ]
Spencer, A. [12 ]
Qi, M. [13 ]
Schecter, J. [14 ]
Amin, H. [14 ]
Qin, X. [15 ]
Deraedt, W. [16 ]
Ahmadi, T. [13 ]
Sonneveld, P. [17 ]
机构：
[1] Eberhard Karls Univ Tubingen, Univ Klinikum Tuebingen, Dept Hematol Oncol Immunol Rheumatol & Pulmonol, Abt Innere Med 2, Tubingen, Germany
[2] Univ Turin, Dept Hematol, Turin, Italy
[3] Mayo Clin Florida, Div Hematol & Med Oncol, Jacksonville, FL USA
[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[5] Charles Univ Prague, Med Dept 1, Dept Clin Haematol, Prague, Czech Republic
[6] Semmelweis Univ, St Laszlo Hosp, Dept Haematol & Stem Cell Transplantat, Budapest, Hungary
[7] Ankara Univ, Dept Hematol, Ankara, Turkey
[8] Irmandade Santa Casa De Misericordia Sao Paulo, Sao Paulo, Brazil
[9] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany
[10] Univ Hosp Salamanca, IBSAL, Salamanca, Spain
[11] Weill Cornell Med Coll, New York, NY USA
[12] Monash Univ, Malignant Haematol & Stem Cell Transplantat Serv, Alfred Hlth, Melbourne, Vic, Australia
[13] Janssen Res & Dev LLC, Spring House, PA USA
[14] Janssen Res & Dev LLC, Raritan, NJ USA
[15] Janssen Res & Dev LLC, Horsham, PA USA
[16] Janssen Res & Dev, Beerse, Belgium
[17] Erasmus MC, Dept Hematol, Rotterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw375.1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
906O
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Wakabayashi, Masashi
    Tsukasaki, Kunihiro
    Miyamoto, Kenichi
    Maruyama, Dai
    Yamamoto, Kazuhito
    Takatsuka, Yoshifusa
    Kusumoto, Shigeru
    Kuroda, Junya
    Ando, Kiyoshi
    Kikukawa, Yoshitaka
    Masaki, Yasufumi
    Kobayashi, Miki
    Hanamura, Ichiro
    Asai, Hiroaki
    Nagai, Hirokazu
    Shimada, Kazuyuki
    Tsukamoto, Norifumi
    Inoue, Yoshiko
    Tobinai, Kensei
    CANCER SCIENCE, 2018, 109 (05) : 1552 - 1561
  • [42] PANOBINOSTATPK/PD IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITHRELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Mu, S.
    Tajima, T.
    Corrado, C.
    Sunami, K.
    Suzuki, K.
    Hino, M.
    Kuroda, Y.
    Shibayama, H.
    Lin, R.
    Waldron, E.
    Binlich, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S49 - S49
  • [43] Bortezomib asociated to dexamethasone in patients with relapsed/refractory multiple myeloma
    de la O, G. M. Maria
    Garcia-Delgado, R.
    Cuesta, M. A.
    Garrido, P.
    Dominguez, B.
    Hernandez, F.
    Galan, M.
    Sanchez, A.
    Garcia-Sanchez, R.
    Lopez, E.
    Perez, E.
    Bailen, A.
    Heiniger, A. I.
    Ramirez, G.
    Garcia, A.
    Jurado, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 482 - 483
  • [44] Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
    Fazio, Francesca
    Franceschini, Luca
    Tomarchio, Valeria
    Rago, Angela
    Garzia, Maria Grazia
    Cupelli, Luca
    Bongarzoni, Velia
    Andriani, Alessandro
    Gumenyuk, Svitlana
    Tafuri, Agostino
    Siniscalchi, Agostina
    Piciocchi, Alfonso
    De Fabritiis, Paolo
    De Rosa, Luca
    di Toritto, Tommaso Caravita
    Annibali, Ombretta
    Cantonetti, Maria
    Petrucci, Maria Teresa
    EJHAEM, 2022, 3 (01): : 121 - 128
  • [45] DARATUMUMAB COMBINED WITH DEXAMETHASONE AND LENALIDOMIDE OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS: REPORT FROM THE MULTIPLE MYELOMA GIMEMA LAZIO GROUP
    Fazio, F.
    Franceschini, L.
    Tomarchio, V.
    Rago, A.
    Garzia, M. G.
    Cupelli, L.
    Bongarzoni, V.
    Rosati, S.
    Gumenyku, S.
    Antolino, G.
    Siniscalchi, A.
    Proietti, G.
    Piciocchi, A.
    De Fabritiis, P.
    De Rosa, L.
    Caravita, T.
    Annibali, O.
    Cantonetti, M.
    Petrucci, M. T.
    HAEMATOLOGICA, 2021, 106 (10) : 92 - 92
  • [46] Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
    Weisel, Katja C.
    Miguel, Jesus San
    Cook, Gordon
    Leiba, Merav
    Suzuki, Kenshi
    Kumar, Shaji
    Cavo, Michele
    Avet-Loiseau, Herve
    Quach, Hang
    Hungria, Vania
    Lentzsch, Suzanne
    Hajek, Roman
    Sonneveld, Pieter
    Wu, Kaida
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Shinsuke Iida
    Tatsuo Ichinohe
    Atsushi Shinagawa
    Kenshi Suzuki
    Naoki Takezako
    Masayuki Aoki
    International Journal of Hematology, 2018, 107 : 460 - 467
  • [48] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Ichinohe, Tatsuo
    Shinagawa, Atsushi
    Suzuki, Kenshi
    Takezako, Naoki
    Aoki, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (04) : 460 - 467
  • [49] Elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)-2-year follow-up
    Palumbo, A.
    Offidani, M.
    Pegourie, B.
    De La Rubia, J.
    Garderet, L.
    Laribi, K.
    Bosi, A.
    Marasca, R.
    Laubach, J.
    Mohrbacher, A.
    Carella, A. M.
    Singhal, A. K.
    Lynch, M.
    Jou, Y-M
    Jakubowiak, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 28 - 28
  • [50] Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naive Relapsed Multiple Myeloma
    Afrough, Aimaz
    Atrash, Shebli
    Paul, Barry
    Ouchveridze, Evguenia
    Ahmed, Nausheen
    Mahmoudjafari, Zahra
    Bashir, Anam
    Alkharabsheh, Omar
    Hashmi, Hamza
    Abdallah, Al-Ola
    CANCERS, 2023, 15 (19)
12345